Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Pretargeted Anti-CD20 Radioimmunotherapy Combined With BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk B-Cell Malignancies

NCT02483000 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT02483000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02483000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Pretargeted Anti-CD20 Radioimmunotherapy Combined With BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk B-Cell Malignancies
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 1
Overall status
Terminated
Start date
February 1, 2017
Completion date
September 2, 2020
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

burkitt lymphoma, cd20-positive neoplastic cells present, diffuse large b-cell lymphoma, indolent non-hodgkin lymphoma, mantle cell lymphoma, recurrent b-cell non-hodgkin lymphoma, refractory mature b-cell non-hodgkin lymphoma